ANI Pharmaceuticals announces commercial availability of Cortrophin Gel

USA-based generic drugmaker ANI Pharmaceuticals (Nasdaq: ANIP) today announced the US commercial availability of Purified Cortrophin Gel (repository corticotropin injection USP).

The commercial launch of Cortrophin Gel, an adrenocorticotropic hormone (ACTH), also known as purified corticotropin, is being led by ANI’s recently established rare disease business unit. Cortrophin Gel is indicated for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), and excess urinary protein due to nephrotic syndrome.

“Patients with certain chronic autoimmune conditions often need additional treatment options,” said Dr Mary Pao Seideman, chief medical officer of ANI. “ACTH therapy can be effective across a number of inflammatory diseases. The reintroduction of Cortrophin Gel gives prescribers another ACTH option, which can mean a greater chance for an effective treatment for some patients,” she noted.